2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Breast Neoplasms
6
Triple Negative Breast Neoplasms
3
Recurrence
3
Prostatic Neoplasms
3
Urinary Bladder Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Non-Small-Cell Lung
2
Turcot syndrome
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Multiple Myeloma
1
Mucopolysaccharidosis I
1
Mesothelioma, Malignant
1
Lymphoma, T-Cell, Peripheral
1
Liposarcoma
1
Inhibition of Autophagy Synergizes Anti-tumor Effect
1
Immunoblastic Lymphadenopathy
1
Hodgkin Disease
1
Genetic Diseases, Inborn
1
Gastrointestinal Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
Gemcitabine
95
Cisplatin
72
Capecitabine
39
Oxaliplatin
38
durvalumab
29
Fluorouracil
27
pembrolizumab
26
Leucovorin
23
S 1 (combination)
19
Nivolumab
14
Irinotecan
14
lenvatinib
13
Bevacizumab
13
tremelimumab
10
130-nm albumin-bound paclitaxel
9
apatinib
8
Trastuzumab
7
Injections
7
Immune Checkpoint Inhibitors
7
Docetaxel
7
Albumin-Bound Paclitaxel
7
Paclitaxel
6
Drug Therapy
6
titanium silicide
5
surufatinib
5
irinotecan sucrosofate
5
gemcitabine-oxaliplatin regimen
5
envafolimab
5
camrelizumab
5
atezolizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
Clinical Trials, Phase II as Topic
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled